Product Description
Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Finafloxacin)
Mechanisms of Action: TOP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Auricular
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada | Egypt
Approved Indications: None
Known Adverse Events: None
Company: MerLion
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Otitis Externa
Phase 2: Dyspepsia|Communicable Diseases|Nephritis|Helicobacter Infections|Gram-Negative Bacterial Infections|Urinary Tract Infections|Pyelonephritis|Otitis Media
Phase 1: Otitis Media|Healthy Volunteers|Pneumonia, Bacterial|Urinary Tract Infections|Helicobacter Infections|Communicable Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2017-002689-30 | P2 |
Completed |
Otitis Media |
2018-09-06 |
|
| C-13-023 | P1 |
Withdrawn |
Otitis Media |
2015-01-01 |
|
| BID for 7 Days | P2 |
Terminated |
Otitis Media |
2014-08-01 |
|
| 2011-006041-14 | P2 |
Completed |
Nephritis|Urinary Tract Infections |
2014-06-15 |